David Arroyo

3.0k total citations · 1 hit paper
49 papers, 1.3k citations indexed

About

David Arroyo is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Nephrology. According to data from OpenAlex, David Arroyo has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Surgery, 18 papers in Cardiology and Cardiovascular Medicine and 16 papers in Nephrology. Recurrent topics in David Arroyo's work include Blood Pressure and Hypertension Studies (9 papers), Lipoproteins and Cardiovascular Health (7 papers) and Dialysis and Renal Disease Management (7 papers). David Arroyo is often cited by papers focused on Blood Pressure and Hypertension Studies (9 papers), Lipoproteins and Cardiovascular Health (7 papers) and Dialysis and Renal Disease Management (7 papers). David Arroyo collaborates with scholars based in Spain, United States and Australia. David Arroyo's co-authors include José Luño, Soledad García de Vinuesa, Marián Goicoechea, Úrsula Verdalles, Jara Ampuero, José Manuel Valdivielso, Àngels Betriu, Elvira Fernández, Borja Quiroga and Nayara Panizo and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and American Journal of Kidney Diseases.

In The Last Decade

David Arroyo

43 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk

2010 618 citations Marián Goicoechea, Soledad García de Vinuesa et al. profile →

Peers

Countries citing papers authored by David Arroyo

Since Specialization

Citations

This map shows the geographic impact of David Arroyo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Arroyo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Arroyo more than expected).

Fields of papers citing papers by David Arroyo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Arroyo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Arroyo. The network helps show where David Arroyo may publish in the future.

Co-authorship network of co-authors of David Arroyo

This figure shows the co-authorship network connecting the top 25 collaborators of David Arroyo. A scholar is included among the top collaborators of David Arroyo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Arroyo. David Arroyo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tubular biomarkers in proteinuric kidney disease: histology correlation and kidney prognosis of tubular biomarkers 2024 ·Clinical Kidney Journal ·Javier Carbayo, Úrsula Verdalles, Francisco Díaz‐Crespo, Alberto Lázaro, (unknown), David Arroyo, (unknown), (unknown), Marián Goicoechea	6
2	Estimated Number Needed to Treat to Avoid a First Hospitalization by Maintaining Instead of Reducing Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Therapy after Hyperkalemia 2024 ·Kidney360 ·Maria Svensson, Michael Fischereder, Paul R. Kalra, Ignacio Sánchez‐Lázaro, Eva Lesén, Stefan Franzén, (unknown), Thomas Cars, Nils Kossack, Philipp Breitbart, David Arroyo	0
3	Tubular biomarkers and histology in lupus nephritis 2024 ·International Journal of Rheumatic Diseases ·Javier Carbayo, Úrsula Verdalles, Francisco Díaz‐Crespo, Alberto Lázaro, (unknown), David Arroyo, (unknown), (unknown), (unknown), Marián Goicoechea	0
4	Seizing the Teachable Moment: A Pilot Study of Preventive Lifestyle Education in the Emergency Department 2024 ·Cureus ·Daniel C. Keyes, David Arroyo, (unknown), (unknown), Jan Miller Polgar, Rita A. Sakr, Syed Shahzad Hasan	0
5	Renin–angiotensin–aldosterone system blockers effect in chronic kidney disease progression in hypertensive elderly patients without proteinuria: PROERCAN trial 2024 ·Hipertensión y Riesgo Vascular ·Ana García‐Prieto, Úrsula Verdalles, A. Jose, David Arroyo, Inés Aragoncillo, Diego Barbieri, Rosa Camacho, María Goicoechea	4
6	Diagnosis and Management of Malnutrition in Patients with Heart Failure 2023 ·Journal of Clinical Medicine ·Alberto Esteban‐Fernández, Rocío Villar‐Taibo, (unknown), David Arroyo, (unknown), (unknown), (unknown), Manuel Méndez‐Bailón, Jose-Ángel Pérez-Rivera, (unknown), (unknown)	26
7	Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study 2021 ·Metabolites ·(unknown), (unknown), (unknown), David Arroyo, (unknown), (unknown), (unknown), Javier Reque, Emilio Sánchez-Álvarez, José Luis Górriz, Borja Quiroga	11
8	Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease 2021 ·BMC Nephrology ·José Luis Górriz, David Arroyo, Luis D’Marco, Roser Torrá, (unknown), María Jesús Puchades, Nayara Panizo, (unknown), (unknown), J.L. Llisterri, Vicente Pallarés‐Carratalá, José Manuel Valdivielso	6
9	The effect of renin–angiotensin–aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria: PROERCAN study. Rationale and design 2020 ·Hipertensión y Riesgo Vascular ·Ana García‐Prieto, Úrsula Verdalles, A. Jose, Eduardo Verde, David Arroyo, Inés Aragoncillo, Tania Liñares, Diego Barbieri, Marián Goicoechea	0
10	Trends in opioid prescribing in Australia: a systematic review* 2019 ·Australian Health Review ·Peter Donovan, David Arroyo, (unknown), Anthony Bell	28
11	Autosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1 2018 ·American Journal of Kidney Diseases ·(unknown), Gemma Bullich, Rosa Miquel, Mónica Furlano, Patricia Ruíz, (unknown), Oliver Valero, Miguel A. García-González, (unknown), Intza Garin, Víctor Martínez, María Vanessa Pérez-Gómez, Xavier Fulladosa, David Arroyo, Alberto Martínez-Vea, (unknown), José Ballarín, Elisabet Ars, Roser Torrá	36
12	Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study 2017 ·PLoS ONE ·Enric Sánchez, Àngels Betriu, David Arroyo, Carolina López‐Cano, Marta Hernández, Ferrán Rius, Elvira Fernández, Albert Lecube	14
13	Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound 2017 ·PLoS ONE ·José Manuel Valdivielso, Àngels Betriu, Montserrat Martínez‐Alonso, David Arroyo, Marcelino Bermúdez-López, Elvira Fernández, (unknown)	20
14	Más allá de los parámetros lipídicos tradicionales en la enfermedad renal crónica 2017 ·Nefrología ·Marcelino Bermúdez-López, Àngels Betriu, José Manuel Valdivielso, (unknown), David Arroyo, Elvira Fernández	5
15	Mineral metabolism factors predict accelerated progression of common carotid intima-media thickness in chronic kidney disease: the NEFRONA study 2016 ·Nephrology Dialysis Transplantation ·(unknown), Àngels Betriu, David Arroyo, (unknown), María Dolores del Pino y Pino, Isabel Martínez, José Manuel Valdivielso, Elvira Fernández, (unknown)	16
16	Toxinas unidas a proteínas: valor añadido en su eliminación con altos volúmenes convectivos 2016 ·Nefrología ·Soraya Abad, Almudena Vega, Borja Quiroga, David Arroyo, Nayara Panizo, Javier Reque, Juan M. López–Gómez	10
17	Estudio de intervención aleatorizado para evaluar la prevalencia de enfermedad ateromatosa y renal ocultas y su impacto en la morbimortalidad: Proyecto ILERVAS 2016 ·Nefrología ·Àngels Betriu, (unknown), (unknown), Montserrat Martínez‐Alonso, David Arroyo, Ferrán Barbé, Miquel Butı́, Albert Lecube, Manuel Portero-Otı́n, Francisco Purroy, Gerard Torres, José Manuel Valdivielso, Elvira Fernández	17
18	Adjuvant Ciprofloxacin for Persistent BK Polyomavirus Infection in Kidney Transplant Recipients 2014 ·SHILAP Revista de lepidopterología ·David Arroyo, Sindhu Chandran, Parsia A. Vagefi, David Wojciechowski	11
19	High-Sensitivity Troponin T Levels in Kidney Transplant Recipients 2012 ·Transplantation Proceedings ·David Arroyo, Borja Quiroga, Nayara Panizo, María Luisa Rodríguez-Ferrero, Nicolás Macías, Javier Reque, F. Anaya, José Luño	7
20	Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD) 2012 ·Nephrology Dialysis Transplantation ·Úrsula Verdalles, Soledad García de Vinuesa, (unknown), Borja Quiroga, Javier Reque, Nayara Panizo, David Arroyo, José Luño	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact